The FDA approved the use of Novo Nordisk's recombinant coagulation factor VIII drug Novoeight, or turoctocog alfa, to prevent and treat bleeding associated with hemophilia A. The firm plans to commercialize the drug shortly after the expiration of a third-party patent in April 2015.

Full Story:
PharmaTimes (U.K.)

Related Summaries